Synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-04. Numbers and descriptions here follow the published literature rather than marketing material.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
AABB publishes a variety of other materials for the blood and biotherapies field, including the standards by which it accredits institutions. Since 1953, the organization has also operated a National Blood Exchange to facilitate transfers of blood products during shortages or when rare blood types are required. On June 1, 2018, Debra BenAvram, FASAE, CAE, became the association's chief executive officer (CEO).
== Other uses == The synthesis of 6-acetyl-1,2,3,4-tetrahydropyridine, an important bread aroma compound, starting from 2-piperidone was accomplished using t-boc anhydride. (See Maillard reaction). The first step in this reaction sequence is the formation of the carbamate from the reaction of the amide nitrogen with boc anhydride in acetonitrile using DMAP as a catalyst.
Since breasts are an external organ and do not contain muscle, exercise cannot improve their shape. They are not protected from external forces and are subject to gravity. Many women mistakenly believe that breasts cannot anatomically support themselves and that wearing a brassiere will prevent their breasts from sagging later in life. Researchers, bra manufacturers, and health professionals have not found any evidence to support the idea that wearing a bra for any amount of time slows breast ptosis. Bra manufacturers are careful to claim that bras only affect the shape of breasts while they are being worn. There is some evidence that bra use reduces the development of Cooper's ligaments, connective tissue that supports breast shape. That atrophy from bra-wearing may therefore lead to more breast sag in the long run, much as the connective tissue in a limb weakens while it is in a cast and must be re-strengthened afterward. Studies have actually documented that, after an initial period of adjustment, women experienced a significant increase in comfort and breast firmness after forgoing bras.
Sources: en.wikipedia.org
Acepromazine † — although it is mostly used in veterinary medicine. Chlorpromazine (Thorazine) Cyamemazine † Dixyrazine † Fluphenazine Levomepromazine‡ Mesoridazine (discontinued)† Perazine Pericyazine‡ Perphenazine Pipotiazine ‡ Prochlorperazine Promazine (discontinued) Promethazine Prothipendyl † Thioproperazine‡ (only English-speaking country it is available in is Canada) Thioridazine (discontinued) Trifluoperazine Triflupromazine (discontinued)†
== Reactivity == Thiophene is considered to be aromatic, although theoretical calculations suggest that the degree of aromaticity is less than that of benzene. The "electron pairs" on sulfur are significantly delocalized in the pi electron system. As a consequence of its aromaticity, thiophene does not exhibit the properties seen for conventional sulfides. For example, the sulfur atom resists alkylation and oxidation.
=== Motion preservation and facet arthroplasty === Independent reviews place TOPS within a broader group of posterior motion-preserving technologies developed to address the trade-off between decompression, stability, and retained segmental motion. Unlike lumbar disc replacement, which principally addresses disc pathology, facet arthroplasty is intended to restore stability after decompression in patients whose disease involves the posterior spinal elements, including the facet joints. Reviews identify preservation of motion and the potential to reduce adjacent-segment disease as key proposed advantages, while emphasizing the importance of patient selection and the need for continued long-term data on implant durability, revision, and adjacent-segment outcomes.
== Biography == In 1993, he immigrated to Canada. Prior to the formation of DVS Sciences. Dr. Baranov, a senior scientist at MDS SCIEX, was a key member of the research team that developed and promoted the Dynamic Reaction Cell®, which remains today at the pinnacle of quadrupole ICP-MS technology. In 2005, together with Scott D. Tanner and Dmitry Bandura, he began independently developing an ICP-TOF-MS based cytometer and became a researcher at the University of Toronto in March 2005. After securing ample funding by 2010 from various sources, including National Institutes of Health, Ontario Institute for Cancer Research (OICR), the Ministry of Research and Innovation, Ontario Centres of Excellence, Health Technology Exchange, and Genome Canada via the Ontario Genomics Institute, and venture capital from 5 AM Ventures, Vladimir and the DVS Sciences team successfully commercialized their technology, leading to the acquisition of DVS Sciences by Fluidigm in 2014 Baranov was a principal scientist at DVS Sciences (and then Fluidigm) developing instrumental concepts and algorithmics that advance the CyTOF® line of products. He also and played a fundamental role in the development of the MaxPar line of metal-labeling reagents until his retirement in 2019.
Sources: en.wikipedia.org
Elton John plays the final UK concert of his farewell tour at Glastonbury 2023, headlining the Pyramid Stage on the festival's final day. 26 June A two-year BBC investigation into the 1993 murder of Stephen Lawrence identifies a sixth suspect who was not charged at the time and is now deceased. Banking giant HSBC announces that it will vacate its 45-storey tower at 8 Canada Square in Canary Wharf and establish a smaller headquarters, possibly in the City of London, when its current lease expires in 2027. The move is attributed to an increase in remote work and less need for in-person office work. Prince William and Geri Horner announce the launch of Homewards, a five-year project aimed at reducing the number of homeless people in the UK. The National Cancer Research Institute announces that it will be closing, amid concerns over its funding. 27 June Boots announces plans to close 300 of its outlets over the next years, saying it will close stores in close proximity to other branches. A report compiled by the Independent Commission for Equity in Cricket (ICEC) says racism, sexism, classism and elitism are "widespread" in English and Welsh cricket. 28 June Daniel Korski withdraws as the Conservative Party's candidate for the 2024 London mayoral election after being accused of groping by novelist and TV producer Daisy Goodwin. A BBC News investigation finds that paedophiles are using Stable Diffusion, a piece of artificial intelligence software, to create lifelike images of child sexual abuse, which are then being distributed through platforms such as Patreon.
=== High-throughput proteomic technologies === Proteomics has steadily gained momentum over the past decade with the evolution of several approaches. Few of these are new, and others build on traditional methods. Mass spectrometry-based methods, affinity proteomics, and micro arrays are the most common technologies for large-scale study of proteins.
Radiation protection areas are spatial areas in which either people can receive certain body doses during their stay or in which a certain local dose rate is exceeded. They are defined in § 36 of the Radiation Protection Ordinance and in §§ 19 and 20 of the X-Ray Ordinance. According to the Radiation Protection Ordinance, radiation protection areas are divided into restricted areas (local dose rate ≥ 3 mSv/hour), control areas (effective dose > 6 mSv/year) and monitoring areas (effective dose > 1 mSv/year), depending on the hazard.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.